An analysis of the costs of 11 FDA-approved adjuvant therapies in the US reveals that these treatments can impose a significant financial burden on society. In Europe, the European Medicines Agency has approved five adjuvant immune-checkpoint inhibitor treatments, with more expected to come in 2022. However, as these immune-checkpoint inhibitors have different mechanisms of action than hormonal and chemotherapeutic adjuvant therapies, it is crucial to establish the correlation between improved disease-free or event-free survival and overall survival. Additionally, the high patient volume in the adjuvant setting is anticipated to put a strain on healthcare systems.

To know more: About the original article click here.